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Abstract
Although dyspnea is frequently encountered in the palliative care setting, its optimal management remains
uncertain. Clinical approaches begin with accurate assessment, as delineated in part one of this two-part series.
Comprehensive dyspnea assessment, which encompasses the physical, emotional, social, and spiritual aspects of
this complex symptom, guide the clinician in choosing therapeutic approaches herein presented as part two.
Global management of dyspnea is appropriate both as complementary to disease-targeted treatments that target
the underlying etiology, and as the sole focus when the symptom has become intractable, disease is maximally
treated, and goals of care shift to comfort and quality of life. In this setting, current evidence supports the use of
oral or parenteral opioids as the mainstay of dyspnea management, and of inhaled furosemide and anxiolytics as
adjuncts. Nonpharmacologic interventions such as acupuncture and pulmonary rehabilitation have potential
effectiveness, although further research is needed, and use of a simple fan warrants consideration given its
potential benefit and minimal burden and cost.
Introduction
Dyspnea is one of the most common symptoms reportedby patients with advanced disease who are nearing the
end of life. Part one of this two-part series on dyspnea for the
palliative care professional describes the burden and mea-
surement of dyspnea.1 Because of its complex biopsychosocial
etiology and manifestations, dyspnea presents a particularly
challenging symptom to manage—yet it is one which, none-
theless, requires an evidence-based symptom management
approach. An armamentarium of both restorative and global
therapies is available to address the modifiable and fixed
components to dyspnea. In this article, we review the goals of
therapy, and the pharmacologic, nonpharmacologic, and
surgical options for treating dyspnea to provide an evidence-
based approach to dyspnea management in the palliative care
setting.
Goals of Therapy
The management of dyspnea seeks to concurrently address
the symptom while identifying and treating underlying cau-
ses. When those causes are no longer reversible, however,
symptom relief becomes the main objective of therapy. In
palliative care, thus, the clinician first determines whether or
not the underlying disease has been maximally treated
without alleviating dyspnea and, if so, focuses on the symp-
tom itself. Global management approaches to dyspnea, with
or without disease-focused interventions, are fundamental
elements in the palliative care toolbox.
Because patients do not experience dyspnea in isolation but
rather in conjunction with other symptoms, concomitant
stressors, and spiritual or existential distress, dyspnea cannot
be fully addressed unless these physical and nonphysical
factors are understood. The clinician can set the stage for
successful symptom management in the setting of advancing
disease by outlining expectations for efficacy with dyspnea
management, dispelling common misconceptions about
dyspnea-relieving medications, and establishing a plan to
continuously reevaluate the patient’s dyspnea. Success is
most likely when as many as possible of the patient’s indi-
vidual dyspnea stressors and concomitant symptoms (i.e.,
anxiety, depression, panic attacks) are identified and ad-
dressed. Figure 1 depicts a model for dyspnea management
1Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina.
2Department of Medicine, Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina, Chapel Hill, North
Carolina.
3Department of Palliative and Supportive Services, Division of Medicine, Flinders University, Bedford Park, South Australia, Australia.
Accepted August 26, 2011.
JOURNAL OF PALLIATIVE MEDICINE
Volume 15, Number 1, 2012
ª Mary Ann Liebert, Inc.
DOI: 10.1089/jpm.2011.0110
106
incorporating the principles of ‘‘total dyspnea’’; the concept of
total dyspnea was described in more detail in the first article
in this series.
In this article we focus on restorative and global interven-
tions for dyspnea management, which are intended to be used
parallel to any ongoing or new disease-modifying therapies or
as stand-alone therapies when modification of the underlying
disease is no longer possible.
Pharmacologic Management of Dyspnea
Opioid efficacy
Opioids are the most studied and employed class of phar-
macologic agents for relieving dyspnea. The effects of opioids
are postulated to be secondary to their effects on ventilatory
response to carbon dioxide, hypoxia, inspiratory flow resis-
tive loading, and decreased oxygen consumption with exer-
cise and at rest in healthy individuals. Additionally, a
vasodilatory effect on pulmonary vascular pressures in ani-
mals has been demonstrated.1 Opioids have historically been
used to treat anxiety and pain, which are often an integral part
of the dyspnea cycle; the positive effects on these symptoms
have been extensively reviewed.2 Proof-of-concept for the use
of opioids in dyspnea was confirmed in a recent report of
measured endogenous opioids during dyspnea. Mahler and
colleagues3 showed during treadmill exercise in opioid-naı̈ve
patients with chronic obstructive pulmonary disease (COPD)
the attenuation of dyspnea by endogenous, circulatory opi-
oids and the reversal of that effect by the administration of an
opioid antagonist, naloxone. The three-fold increase in en-
dogenous opioids from rest to end-exercise suggests a
mechanism by which exogenous opioids may also benefit the
patient experiencing dyspnea.
Opioids, most commonly morphine, have been studied in
oral, parenteral, and nebulized forms in randomized con-
trolled trials. One systematic review and meta-analysis4 of
placebo-controlled trials in dyspnea associated with any dis-
ease showed a statistically significant effect for oral or par-
enteral opioids only. In subgroup analysis, a positive effect of
nebulized opioids was not seen, although the authors admit
the available studies were of poor quality and all were very
small. Two recent systematic reviews5,6 in cancer patients also
looking at different modalities of opioid administration ar-
rived at similar conclusions about the efficacy of both oral and
parenteral opioids. Although one small study by Bruera and
coworkers7 showed a comparable level of dyspnea relief
achieved with nebulized morphine and subcutaneous mor-
phine, seven other placebo-controlled trials have not repli-
cated these results.
Two important clinical trials furnish the basis for recom-
mendations for opioid dosing and titration. The single largest
double-blind, controlled trial by Abernethy et al.8 enrolled 48
opioid-naı̈ve patients with breathlessness, most of whom had
COPD. In this cross-over design, participants were assigned
to 20-mg once-daily sustained-release oral morphine sulfate
or placebo for 4 days, followed by 4 days of the alternative. In
the morphine arm, significant benefits in dyspnea and in-
somnia were reported. In another study in patients with prior
opioid exposure, titrating to significantly higher doses (50%
above baseline) conferred no additional benefit compared
with increasing the dose in smaller increments (25% above
baseline) for relieving persistent dyspnea.9 Thus, these au-
thors recommend starting at 10 to 20-mg sustained-release
morphine daily in divided doses, with active evaluation and
gradual titration to desired effect.
Currow and colleagues recently completed a Phase II dose
increment study to determine a minimum effective daily dose
for opioids for dyspnea improvement and to evaluate whether
or not the clinical benefit is maintained over time.10 Eighty-five
participants were given escalating doses of sustained-release
oral morphine, starting at 10 mg per day and increasing if they
experienced less than a 10% reduction over their own baseline
by 10 mg to a maximum 30 mg per day. Overall, in 65% of
patients opioids reduced dyspnea by at least 10% (i.e., 65%
response rate); calculated number needed to treat (NNT) was
1.5. Remarkably, for 70% of patients the beneficial dose was
10 mg per day and sustained benefit for 3 months was ob-
served in 53% of patients at any dose. This was the first study
to demonstrate that low doses of sustained opioids have a
significant and persistent therapeutic effect on dyspnea.
Common nonmorphine opioids have been investigated in a
limited number of studies. A small study of oral hydro-
morphone with 14 patients showed significant dyspnea relief
at a mean dose of 2.5 mg every 6 hours.11 A recent pilot trial of
nebulized or systemic hydromorphone versus nebulized sa-
line demonstrated dyspnea improvement in all groups,
FIG. 1. Biopsychosocial model of dyspnea management.
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suggesting the importance of a possible placebo effect for any
dyspnea intervention.12 Trials of nebulized fentanyl have
been plagued by slow accrual13; the only reports of efficacy
come from small case series that achieved promising results
using the oral, transmucosal form.14,15
Opioid safety
The usual barrier to the use of opioids as the first-line,
pharmacologic treatment for dyspnea is fear of respiratory
depression and accelerated death. Historically, opioids were
used to alleviate dyspnea from the late-nineteenth century
until the 1950s when literature highlighted concerns about the
effects of opioids on respiratory depression and CO2 reten-
tion.16 This fear has been shown to be largely unfounded.
Examining changes in respiratory parameters (peripheral ar-
terial oxygen saturation [SaO2], transcutaneous arterial pres-
sure of carbon dioxide [tcPaCO2], respiratory rate, and pulse
rate) in dyspneic palliative care patients, Clemens et al.17,18
demonstrated significant decrease in respiratory rate and
improvement in dyspnea with titration with morphine or
hydromorphone but no significant changes in other respira-
tory parameters, indicating no opioid-induced respiratory
depression. The studies administered oral opioids in modest
doses titrated to dyspnea relief. The authors concluded that,
with proper titration, opioids can be used to relieve dyspnea
by decreasing respiratory rate while avoiding iatrogenic hy-
percarbia or hypoxia. These conclusions are also supported in
a recent systematic review.4 Additionally, the study by Cur-
row et al. reviewed prospectively more than 30 patient years
of data with no events of respiratory depression or cognitive
impairment in a frail, older population.10 These demonstrated
benefits, and the lack of evidence of accelerated death, have
led the American College of Chest Physicians in its ‘‘2010
Consensus Statement on the Management of Dyspnea in Pa-
tients with Advanced Lung or Heart Disease’’ to recommend
that physicians titrate oral and/or parental opioids for the
relief of dyspnea.19
Anxiolytics
The use of benzodiazepines and selective serotonin re-
uptake inhibitors (SSRIs) rests on the rationale that: patients
with anxiety disorders more frequently report dyspnea, pa-
tient reports of dyspnea usually cluster with the presence of
anxiety or depression, and treating anxiety/depression may
thus help ameliorate dyspnea. With SSRIs, there may also be a
direct effect on centers that control the perception of breath-
lessness.
Benzodiazepines have been studied both as single agents
and paired with opioids. The initial report in 1980 of diaze-
pam efficacy was an exploratory study of four patients with
severe obstructive airway disease and without severe hypoxia
at rest.20 Subsequent clinical trials of clorazepate,21 alprazo-
lam,22 and diazepam23 have failed to show any benefit when
compared with placebo. One trial24 compared three arms:
morphine alone, midazolam alone, and morphine plus mid-
azolam; the study showed a modest benefit with the addition
of the benzodiazepine to morphine leading to reduction in
dyspnea intensity and decreased breakthrough dyspnea.
Importantly, this study enrolled advanced cancer patients
with a life expectancy of less than one week (30% of patients in
each arm died during the study) and would be difficult to
generalize to the majority of the palliative care population.
Although the use of midazolam may raise concerns about
adverse events and difficulty of administration, a recent
publication by Navigante and coworkers25 demonstrates both
the equal efficacy and the overall safety of oral midazolam
versus oral opioid. Sixty-three patients with severe dyspnea
(mean dyspnea > 8.5 on a 0 to 10 numerical rating scale) were
randomized to either oral morphine or oral midazolam at
starting doses of 3 mg and 2 mg, respectively. Doses were
increased to an effective dose using a fast-titration schedule
over 2 hours; patients were then followed daily for 5 days. At
least 50% of both patient groups had dyspnea alleviated
during the 2-hour titrating phase, with no significant differ-
ence between agents. During the 5-day follow-up phase,
midazolam proved superior to morphine in controlling both
baseline and breakthrough dyspnea. The most common ad-
verse event, with no significant difference between the two
agents, was mild somnolence that did not interfere with fur-
ther medical workup. This recent report is the first to show
efficacy of a benzodiazepine in an outpatient setting, with
reasonable reported safety profiles. However, many questions
about the role of midazolam remain; the duration of the Na-
vigante studies are very short and the population severely
dyspneic, making assessments of safety and generalizability
of findings difficult.26 The model of titration also presupposes
that the dose received in rapid titration is related to the
maintenance dose. Compatibility of the doses of opioids and
benzodiazepine chosen has not been demonstrated.
Inhaled furosemide
Furosemide has been postulated to reduce dyspnea be-
cause of its inhibitory effect on the cough reflex, preventive
effect on bronchoconstriction in asthma, and possible indirect
actions on sensory nerve endings in the airway epithelium.
Inhaled furosemide has been studied in patients with
cancer27,28 and COPD,29 as well as in normal participants.30 In
placebo-controlled studies in COPD patients, Ong et al.29 and
Jensen et al.31 both showed a significant improvement in
dyspnea scores with exercise; the latter study also showed a
benefit in exercise endurance time. A recent double-blind
study of 15 patients (primarily lung cancer) randomized
participants to receive either nebulized furosemide 40 mg,
nebulizer 0.9% saline, or no treatment in random order over 3
consecutive days. Measured outcomes included a number
reading test (mean numbers read during one breath) and arm
exercise test (responses measured on modified Borg scale). Six
of the 15 patients reported dyspnea relief with any nebulized
treatment, but there remained no statistical superiority of ei-
ther the saline or furosemide. Although seemingly small in its
total sample size, this represents the largest controlled study
in cancer patients and reproduces findings from another
study with seven cancer patients that investigated a smaller
20-mg furosemide dose.32 To date most reports of inhaled
furosemide benefits in cancer patients are limited to case re-
ports and case series28,33 34; the varying dosing and delivery
methods limit cross-report comparisons.
Oxygen
Supplemental oxygen is one of the interventions most fre-
quently requested by patients35 and implemented by hospi-
tals to relieve dyspnea.36 Studies in COPD patients have
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demonstrated both survival and quality-of-life advantages
with oxygen therapy in the presence of significant hypoxemia.
Two landmark trials from almost 30 years ago demonstrate a
clear survival advantage with continuous or nocturnal oxy-
gen in hypoxemic COPD patients whose PaO2 assessments
were £ 55 mm Hg or < 60 mm Hg in the setting of cor pul-
monale or other evidence of end-organ damage due to hyp-
oxia.37,38 A recent study observed that, with ambulatory
oxygen therapy in patients without resting hypoxemia but
with oxygen desaturation during activity, 68% of COPD pa-
tients reported improved health-related quality of life and
35% reported less dyspnea.39
Palliative oxygen treatment is usually considered to be
oxygen therapy administered specifically for the relief of
dyspnea when PaO2 is < 55 mm Hg, and the reimbursement
criteria for long-term home oxygen therapy are not met.
Cranston and colleagues40 recently published a Cochrane re-
view of palliative oxygen therapy in adult patients with
chronic terminal illness in nonacute settings. Eight random-
ized controlled trials measuring dyspnea by an ordinal scale
(Visual Analog Scale, Borg or modified Borg, or 0 to 10 Nu-
merical Rating Scale) in patients with cancer, heart failure,
and kyphoscoliosis, but not COPD alone, were included. In-
dividually, all of the included studies had small study pop-
ulations and most were underpowered to detect a 25%
difference in dyspnea with the given interventions. Conflict-
ing findings made the overall results inconclusive. In cancer
dyspnea, studies examining palliative oxygen therapy use
both at rest and with activity reported differing results; in
cardiac dyspnea, high-flow but not low-flow oxygen pro-
vided relief during exercise; and in kyphoscoliosis, one study
reported significant improvement in dyspnea and hypoxia
with exercise. The authors of the systematic review ultimately
concluded that the available studies fail to demonstrate a
consistent effect of palliative oxygen for dyspnea, but that
there remain certain populations of patients that significantly
benefit from this intervention. Other systematic reviews in
cancer dyspnea5,41 have suggested that oxygen benefit may be
seen only in patients with more severe hypoxemia.
To clarify the role of palliative oxygen for refractory dys-
pnea, Abernethy and colleagues conducted a large, interna-
tional, randomized, controlled, double-blind study of
palliative oxygen versus medical air (i.e., room air with am-
bient partial pressure of oxygen) for nonhypoxemic patients
(PaO2 > 55 mm Hg).47 Participants received either gas via
concentrator through nasal cannulae at 2 L per minute and
were asked to use it for more than 15 hours per day for 7 days.
Participants rated their breathlessness and other measures
twice per day. Neither gas demonstrated superiority in im-
proving quality of life or relieving the sensation of breath-
lessness. Interestingly, both dyspnea and quality of life
improved over the study period in both arms, suggesting that
patients may experience benefit derived from the sensation of
moving air alone, rather than from the properties of a specific
gas such as oxygen. Further analysis suggested that patients
with higher baseline dyspnea derived more benefit prefer-
entially from palliative oxygen than did patients with lower
baseline dyspnea, and that most benefit from the intervention
occurred in the first 48 hours, with nearly all symptomatic and
functional improvements manifesting in the first 3 days. The
study clearly calls into question the common palliative care
practice of prescribing oxygen therapy for refractory dyspnea;
if medical gas is prescribed, then patients should be moni-
tored closely and the intervention discontinued if no benefit is
realized after 3 days. Because some patients who might ben-
efit from oxygen therapy may not want to receive it42 and
because the data on dyspneic patients’ treatment preferences
are not conclusive, palliative oxygen should be delivered only
with careful consideration of the intervention’s potential
benefit versus patient burden and costs43; this conversation
should include the patient and caregiver, whenever possible.
The utility of an ‘‘N of 1’’ trial to address this cannot be
overemphasized.44
An interesting head-to-head comparison of opioid versus
oxygen therapy in a German palliative care unit was recently
reported.45 To investigate the comparative effect of these two
interventions on respiratory rate, dyspnea intensity, SaO2,
and PaCO2, this study enrolled 46 terminally ill patients with
baseline hypoxemia ( < 90% SaO2) or normoxemia but without
uncontrolled symptoms. Patients received either 4 L of sup-
plemental oxygen via nasal cannula, or titrated basal opioids,
with the option for breakthrough opioids for symptom relief.
Patients receiving opioids were more likely to have dyspnea
intensity reduced. The study demonstrated no benefit of ox-
ygen at rest in either hypoxemic or normoxemic patients.
Additionally, no increased hypercarbia was seen in the opioid
group versus the oxygen supplementation group.
Nonpharmacologic Management of Dyspnea
Results of the palliative oxygen trial by Abernethy et al.,46
described above, suggest that simple interventions based on
the movement of air may relieve dyspnea for certain patients
in a safe, cost-effective manner. A randomized, cross-over
trial of a hand-held electric fan directed toward the face versus
toward the leg for 5 minutes showed significant decrease in
dyspnea when the moving air was directed toward the face.
Participants had advanced disease but were not receiving
supplemental oxygen. This study of 50 patients also demon-
strated continued benefit in some patients, and new benefit in
others, during the 10-minute washout period after cessation of
the fan intervention.47
Pulmonary rehabilitation may be beneficial for patients
with stage 3 or 4 COPD by GOLD (Global Initiative for
Chronic Obstructive Lung Disease) criteria or for patients
with severe dyspnea out of proportion to the severity of the
disease.48 The most common model for pulmonary rehabili-
tation in the United States is a multidisciplinary, hospital-
based, outpatient program, but the service may also be pro-
vided in home-based, community-based, or inpatient settings.
These often consist of supervised 3- or 4-hour sessions of low-
or high-intensity aerobic exercise, three times per week for 6 to
12 weeks. Many clinical trials have demonstrated this inter-
vention’s benefits: improvement in exercise capacity (in in-
cremental, constant work rate, and timed walking tests),
reduction in severity of dyspnea, and increase in health-re-
lated quality of life.49 Dyspnea in COPD patients is thought to
be a consequence of dynamic hyperinflation resulting from
increased ventilatory demand, and inadequate time allowed
for expiration, when patients are active. Exercise mitigates
this process by lowering ventilatory demand, resulting in a
slowing of respiration at a given level of exercise. The re-
sulting longer expiratory time produces less dynamic hyper-
inflation and ultimately less dyspnea.
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In a prospective study of 45 people with lung cancer, most
with resectable disease and good performance status, a pro-
gram of aerobic exercise for 30 minutes per day significantly
decreased ‘‘dyspnea’’ and ‘‘coughing’’ scores over a 4-week
period.50 Similarly, most studies of exercise for dyspnea in
cancer patients demonstrate benefits in patients who are ei-
ther awaiting or recovering from lung resection. A retro-
spective review of cancer patients who were not in the
perioperative setting and who were referred to a pulmonary
rehabilitation center over a one-year period, most of whom
had COPD as a comorbid condition, showed improved dis-
tance with the 6-minute walk test but no improvement in
perceived dyspnea at rest or after the 6-minute walk.51
Although some palliative care patients may benefit from
pulmonary rehabilitation, its significant cost ($2200 per par-
ticipant in a model 8-week program),52 time commitment, and
unproven durability of benefit in people who are deteriorat-
ing systemically49 make its use not generalizable to all palli-
ative care populations.
For a comprehensive review and discussion of non-
pharmacologic management of dyspnea, the reader is referred
to a recently published Cochrane review.53
Surgical/Procedural Interventions for Dyspnea
Thoracic malignancies can cause dyspnea from obstruction
of airways by mass lesions or lung parenchyma through
pleural effusions. Symptomatic pleural effusions can be ad-
dressed by many surgical/procedural approaches including
mechanical and chemical pleurodesis, pleural tunneled cath-
eter placement, and open or video-assisted thoroscopic sur-
gery (VATS) pleurectomy. Tunneled pleural catheters such as
the PleurX (Care Fusion, San Diego, CA) catheter have
gained recent favor because of their ease of placement and low
complication rate. Recently Monsky and coworkers54 re-
ported in a 31-patient case series an increase in quality of life
and improvement of symptoms and comfort after catheter
placement in patients with end-stage malignancies. Further-
more, Olden et al. recently conducted a decision analysis to
assess cost-effectiveness of the PleurX catheter versus talc
pleurodesis for malignant pleural effusion. Results showed
similar effectiveness, with a distinct cost-effectiveness advan-
tage for pleurodesis by about 0.006 quality-adjusted life years
(QALYs) at an $840 lower cost. Possibly due to lower supply
costs, cost-effectiveness increased (reducing cost to $100,000/
QALY) with catheters for patients with a prognosis of less than
6 weeks.55 A prospective study of interventional bronchos-
copy to relieve dyspnea and improve quality of life in patients
with malignant central respiratory obstructions showed dys-
pnea improvement in 85% of patients; approximately half
reported an improvement in overall quality of life.56
Lung volume reduction surgery (LVRS) is considered in
patients with severe COPD who are symptomatic despite
maximal medical therapy and pulmonary rehabilitation.
LVRS plus optimal medical therapy is superior to medical
therapy alone in treating certain subsets of patients with se-
vere emphysema. In patients with predominantly upper lobe
emphysema and low exercise capacity, LVRS improves dys-
pnea and exercise tolerance and confers a survival advan-
tage.57 Furthermore, LVRS has been shown to be superior in
reducing need for supplemental oxygen up to 2 years post-
procedure58 and decreasing frequency of COPD exacerba-
tions.59 The procedure, however, has limitations: 90-day
postoperative mortality is approximately 5%, and major
pulmonary and cardiac postoperative morbidity can exceed
20%.60
Emerging and Complementary Therapeutics
Heliox is a mixture of oxygen (generally 20% to 28%) and
helium (72% to 80%). Helium, a less dense gas than the ni-
trogen that is naturally occurring in ambient air, is thought to
produce less airway resistance when inhaled with oxygen.
Compared with oxygen alone, Heliox has been shown to in-
crease exercise tolerance in mildly hypoxic patients with
moderate to severe COPD,61 and to increase SaO2, improve
exercise tolerance, and decrease dyspnea scores in lung cancer
patients.62 Its widespread use remains limited by its expense
($30 to $70 for 8 hours of use),63 cumbersome logistics (use
requires a nonrebreathing mask; gas is delivered in large
tanks), lack of routine availability in most medical centers,
and lack of guidelines for patient selection.
Acupuncture, which involves carefully positioned inser-
tion and manipulation of filiform needles,also has been
studied as a minimally invasive approach to dyspnea. A
randomized controlled trial64 of 24 COPD patients (mean age
64 years) with disabling dyspnea compared 13 sessions of true
acupuncture versus sham acupuncture (i.e., placebo in which
needles are placed at points not corresponding to acupuncture
points) for 3 weeks. Patients treated with true acupuncture
had less subjective breathlessness and performed better in a
6-minute walk test than did those receiving sham acupuncture.
A more recent placebo-controlled study of 36 patients, mostly
with COPD, found a significant improvement in VAS scores,
observed in both acupuncture and placebo (mock transcuta-
neous electrical nerve stimulator) groups with no significant
between-group difference.65 A prospective study of 20 patients
with cancer-related dyspnea at rest treated with acupuncture
reported that 70% of participants experienced significant dys-
pnea improvement; benefit peaked at 90 minutes and lasted up
to 6 hours.66 Although more recent studies are now being re-
ported demonstrating mixed results on its effect on dyspnea,
the latest systematic review5 and Cochrane Database review53
found inadequate evidence to recommend acupuncture as a
routine intervention for dyspnea control in cancer patients.
Conclusions about its efficacy in COPD and other primary re-
spiratory diseases are premature; further studies are needed to
fill this gap.
Supplemental nutrition has been studied to counteract the
muscle wasting and weight loss that are common in patients
with COPD. These changes adversely affect respiratory
muscle function, health status, and exercise capacity67 and
may result from inadequate dietary intake68 relative to an
increase in resting energy expenditure (REE)69 or imbalance in
protein synthesis and turnover.70,71 Several overviews, in-
cluding a recent meta-analysis,72 Cochrane Database re-
view,73 and systematic review74 have all concluded that
nutritional supplementation alone does not change mean-
ingful outcomes in patients with COPD. A recent trial ran-
domized 32 patients with moderate to severe COPD to
exercise with breath retraining, upper and lower limb exer-
cises, respiratory muscle stretching and exercises, and walk-
ing daily, supplemented with additional 400 kcal per day
through a sports drink, versus dyspnea education and normal
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diet. The authors found that adding low-intensity regular
exercise training to nutritional supplementation did result in a
modest benefit in weight gain, increased exercise capacity,
and improved health-related quality of life, including dys-
pnea intensity.75 Further studies using co-interventions with
nutritional supplementation are needed to expand patient-
controlled options for dyspnea control.
Tris-hydroxymethyl aminomethane (THAM), an intrave-
nous compound that works as a hydrogen ion acceptor, has
been shown in experimental models to reduce minute venti-
lation and subjective dyspnea in healthy subjects.76 The idea
that artificially inducing a metabolic alkalosis and decreasing
respiratory drive for acidosis compensation, as previously
shown with sodium bicarbonate,77 is intriguing but requires
further study.
Summary
Treatment goals for dyspnea center on identifying revers-
ible anatomic and physiologic causes, intervening upon those,
and in parallel, implementing global therapies for dyspnea
management (Fig. 2). Although the evidence base continues to
build to support widespread use of stalwart therapies in-
cluding opioids, oxygen in hypoxemic patients, and pulmo-
nary rehabilitation, recent studies with benzodiazepines,
medical air in normoxemic patients, and acupuncture are
FIG. 2. Global therapies for dyspnea management.
FIG. 3. Treatment options for dyspnea.
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adding to our understanding of how to incorporate other
agents into a comprehensive dyspnea management plan.
Figure 3 summarizes options and conclusions on efficacy
from the current literature base.
Conclusion
Dyspnea is a significant and disabling symptom experi-
enced by many people during the end of life. Palliative care
providers must be comfortable in developing a systematic
treatment approach that includes strategies aimed at re-
versing anatomic and physiologic causes and global thera-
pies when underlying causes cannot be modified. Oral or
parenteral opioids remain the standard initial therapy,
whereas anxiolytics or inhaled furosemide are important
adjuncts to consider as more data become available. Al-
though oxygen is called upon often to alleviate dyspnea, its
use should not be considered automatic and certainly should
not be continued if patients do not experience clinically
relevant relief in a brief time period with its use. Several
nonpharmacologic options should also be considered. Fur-
ther study, especially investigating interventions for the
psychosocial, spiritual, and existential components that
contribute to ‘‘total dyspnea,’’ is needed to provide evidence-
based interventions for a true multidisciplinary approach to
refractory dyspnea.
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